Blogs

Drug delivery systems have undergone significant transformation over the past decade. The industry has moved beyond conventional vials and ampoules toward prefilled syringes, autoinjectors, wearable injectors, inhalers, and combination products that integrate drug, device, and packaging into a single therapeutic platform. These formats are designed to enhance dosing accuracy, patient convenience, and treatment adherence. As delivery systems become more complex, packaging performance expectations have also intensified. Container Closure Integrity Testing (CCIT) has evolved alongside these changes, offering science-based methods to evaluate whether packaging systems maintain a sterile barrier throughout their lifecycle.

Why CCIT Matters More Than Ever?

Advanced drug delivery systems often involve biologics, cell and gene therapies, and highly potent formulations that display sensitivity to oxygen, moisture, and microbial ingress. Many of these products are manufactured in low volumes, stored under controlled temperatures, and distributed globally. The packaging must tolerate mechanical stress, thermal cycling, and extended storage without compromising closure integrity.

Unlike traditional containers, modern delivery systems frequently include multiple seals, elastomeric components, adhesive bonds, and interfaces between materials with different physical properties. Each interface introduces potential pathways for leakage. CCIT provides a structured approach to evaluate these risks by generating quantitative, repeatable data on package integrity. Regulatory expectations, reflected in guidance such as USP <1207>, increasingly emphasize deterministic test methods that can demonstrate package performance with traceable evidence rather than subjective interpretation.

Limitations of Traditional Integrity Testing

Historically, integrity evaluation relied heavily on probabilistic methods such as dye ingress, bubble emission, and microbial challenge testing. While these techniques have long been used, they present limitations when applied to advanced delivery systems. Many are destructive, making them unsuitable for high-value products or small batch sizes. Others depend on operator judgment, which introduces variability and limits reproducibility.

In addition, traditional methods often struggle to detect microleaks that fall below visual or microbial thresholds yet still allow long-term ingress of gases or moisture. For combination products with complex geometries, these methods may fail to adequately challenge all potential leak paths. As delivery systems become more intricate, reliance on legacy approaches can leave gaps in package evaluation strategies.

Advanced CCIT Technologies Powering Modern Drug Delivery

Vacuum Decay technology: Vacuum Decay technology is the most practical and sensitive vacuum-based leak test method. It detects leaks by monitoring pressure changes within a sealed test chamber containing the package under evaluation. After a controlled vacuum is applied, any loss of pressure indicates the presence of a leak, allowing quantitative measurement of package integrity. This method is suitable for both rigid and flexible packaging formats and can be configured for a wide range of advanced drug delivery systems, including prefilled syringes, cartridges, blister packs. 

HVLD technology: HVLD is a non-destructive highly sensitive technology for container closure integrity for wide range of liquid filled parenteral products. identifies leaks by applying a low electrical potential across a sealed container filled with conductive liquid. When a breach exists, even at a microscopic level, current passes through the leak path and is detected by the system. This technology is proven to be a highly sensitive leak detection method for various types of liquid-filled packaging including, but not limited to pre-filled syringes, vials, cartridges and ampoules.

Helium Leak Detection: Helium leak detection is a deterministic testing method used to identify and measure leaks in sealed packages by using helium gas as a tracer. During testing, helium is introduced into or around the package, and any escaping gas is measured using a highly sensitive detector. These techniques are widely applied during feasibility studies, method development, and validation to define detection limits and establish correlations with Maximum Allowable Leakage Limits (MALL). The high sensitivity of helium testing supports detailed evaluation of package performance during design qualification and comparative studies.

As drug delivery systems continue to advance, packaging integrity assessment must keep pace with increased complexity and heightened performance expectations. CCIT has transitioned from a compliance-driven activity to a data-driven discipline that supports product understanding, risk management, and regulatory alignment. By adopting deterministic technologies, manufacturers can evaluate package integrity with greater confidence across diverse delivery platforms. In an environment shaped by innovation in therapeutics and devices, CCIT provides a structured framework for assessing whether packaging systems perform as intended throughout development, distribution, and patient use.